Multidisciplinary focus on cyclosporin a

Carlo Salvarani, Luigi Boiardi, Pierluigi Macchioni, Nicolò Pipitone, Mariagrazia Catanoso, Paolo Pigatto

Research output: Contribution to journalArticle

Abstract

Cyclosporin A (CsA) has been proved to be effective in the treatment of severe cutaneous psoriasis and psoriatic arthritis (PsA). In psoriasis, CsA therapy can be used as: (1) intermittent short-course therapy; (2) continuous longterm therapy; (3) crisis intervention; and (4) a combination of sequential and rotational therapy. Several open prospective studies have shown the short-term efficacy of CsA in PsA. While there were no randomized controlled trials (RCT) comparing CsA to placebo, 3 published controlled trials compared CsA to other disease modifying antirheumatic drugs (DMARD). These studies support the efficacy of CsA in patients with PsA and peripheral arthritis. However, no conclusions can be drawn on the efficacy of CsA for dactylitis and axial disease. Longterm studies have shown the persistent efficacy and safety of CsA in PsA. The beneficial effects of CsA in angiogenesis-related diseases such as PsA and cutaneous psoriasis may also be mediated by its ability to block the angiogenic effects induced by vascular endothelial growth factor.

Original languageEnglish
Pages (from-to)52-55
Number of pages4
JournalJournal of Rheumatology
Volume36
Issue numberSUPPL. 83
DOIs
Publication statusPublished - Aug 2009

Fingerprint

Cyclosporine
Psoriatic Arthritis
Psoriasis
Crisis Intervention
Therapeutics
Skin
Antirheumatic Agents
Aptitude
Vascular Endothelial Growth Factor A
Arthritis
Randomized Controlled Trials
Placebos
Prospective Studies
Safety

Keywords

  • Cyclosporin A
  • Psoriasis
  • Psoriatic arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Salvarani, C., Boiardi, L., Macchioni, P., Pipitone, N., Catanoso, M., & Pigatto, P. (2009). Multidisciplinary focus on cyclosporin a. Journal of Rheumatology, 36(SUPPL. 83), 52-55. https://doi.org/10.3899/jrheum.090225

Multidisciplinary focus on cyclosporin a. / Salvarani, Carlo; Boiardi, Luigi; Macchioni, Pierluigi; Pipitone, Nicolò; Catanoso, Mariagrazia; Pigatto, Paolo.

In: Journal of Rheumatology, Vol. 36, No. SUPPL. 83, 08.2009, p. 52-55.

Research output: Contribution to journalArticle

Salvarani, C, Boiardi, L, Macchioni, P, Pipitone, N, Catanoso, M & Pigatto, P 2009, 'Multidisciplinary focus on cyclosporin a', Journal of Rheumatology, vol. 36, no. SUPPL. 83, pp. 52-55. https://doi.org/10.3899/jrheum.090225
Salvarani C, Boiardi L, Macchioni P, Pipitone N, Catanoso M, Pigatto P. Multidisciplinary focus on cyclosporin a. Journal of Rheumatology. 2009 Aug;36(SUPPL. 83):52-55. https://doi.org/10.3899/jrheum.090225
Salvarani, Carlo ; Boiardi, Luigi ; Macchioni, Pierluigi ; Pipitone, Nicolò ; Catanoso, Mariagrazia ; Pigatto, Paolo. / Multidisciplinary focus on cyclosporin a. In: Journal of Rheumatology. 2009 ; Vol. 36, No. SUPPL. 83. pp. 52-55.
@article{a1ebe5ddd1fa434bbcafaf9c4971f554,
title = "Multidisciplinary focus on cyclosporin a",
abstract = "Cyclosporin A (CsA) has been proved to be effective in the treatment of severe cutaneous psoriasis and psoriatic arthritis (PsA). In psoriasis, CsA therapy can be used as: (1) intermittent short-course therapy; (2) continuous longterm therapy; (3) crisis intervention; and (4) a combination of sequential and rotational therapy. Several open prospective studies have shown the short-term efficacy of CsA in PsA. While there were no randomized controlled trials (RCT) comparing CsA to placebo, 3 published controlled trials compared CsA to other disease modifying antirheumatic drugs (DMARD). These studies support the efficacy of CsA in patients with PsA and peripheral arthritis. However, no conclusions can be drawn on the efficacy of CsA for dactylitis and axial disease. Longterm studies have shown the persistent efficacy and safety of CsA in PsA. The beneficial effects of CsA in angiogenesis-related diseases such as PsA and cutaneous psoriasis may also be mediated by its ability to block the angiogenic effects induced by vascular endothelial growth factor.",
keywords = "Cyclosporin A, Psoriasis, Psoriatic arthritis",
author = "Carlo Salvarani and Luigi Boiardi and Pierluigi Macchioni and Nicol{\`o} Pipitone and Mariagrazia Catanoso and Paolo Pigatto",
year = "2009",
month = "8",
doi = "10.3899/jrheum.090225",
language = "English",
volume = "36",
pages = "52--55",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "SUPPL. 83",

}

TY - JOUR

T1 - Multidisciplinary focus on cyclosporin a

AU - Salvarani, Carlo

AU - Boiardi, Luigi

AU - Macchioni, Pierluigi

AU - Pipitone, Nicolò

AU - Catanoso, Mariagrazia

AU - Pigatto, Paolo

PY - 2009/8

Y1 - 2009/8

N2 - Cyclosporin A (CsA) has been proved to be effective in the treatment of severe cutaneous psoriasis and psoriatic arthritis (PsA). In psoriasis, CsA therapy can be used as: (1) intermittent short-course therapy; (2) continuous longterm therapy; (3) crisis intervention; and (4) a combination of sequential and rotational therapy. Several open prospective studies have shown the short-term efficacy of CsA in PsA. While there were no randomized controlled trials (RCT) comparing CsA to placebo, 3 published controlled trials compared CsA to other disease modifying antirheumatic drugs (DMARD). These studies support the efficacy of CsA in patients with PsA and peripheral arthritis. However, no conclusions can be drawn on the efficacy of CsA for dactylitis and axial disease. Longterm studies have shown the persistent efficacy and safety of CsA in PsA. The beneficial effects of CsA in angiogenesis-related diseases such as PsA and cutaneous psoriasis may also be mediated by its ability to block the angiogenic effects induced by vascular endothelial growth factor.

AB - Cyclosporin A (CsA) has been proved to be effective in the treatment of severe cutaneous psoriasis and psoriatic arthritis (PsA). In psoriasis, CsA therapy can be used as: (1) intermittent short-course therapy; (2) continuous longterm therapy; (3) crisis intervention; and (4) a combination of sequential and rotational therapy. Several open prospective studies have shown the short-term efficacy of CsA in PsA. While there were no randomized controlled trials (RCT) comparing CsA to placebo, 3 published controlled trials compared CsA to other disease modifying antirheumatic drugs (DMARD). These studies support the efficacy of CsA in patients with PsA and peripheral arthritis. However, no conclusions can be drawn on the efficacy of CsA for dactylitis and axial disease. Longterm studies have shown the persistent efficacy and safety of CsA in PsA. The beneficial effects of CsA in angiogenesis-related diseases such as PsA and cutaneous psoriasis may also be mediated by its ability to block the angiogenic effects induced by vascular endothelial growth factor.

KW - Cyclosporin A

KW - Psoriasis

KW - Psoriatic arthritis

UR - http://www.scopus.com/inward/record.url?scp=70349907644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349907644&partnerID=8YFLogxK

U2 - 10.3899/jrheum.090225

DO - 10.3899/jrheum.090225

M3 - Article

C2 - 19661542

AN - SCOPUS:70349907644

VL - 36

SP - 52

EP - 55

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - SUPPL. 83

ER -